Biocon is currently trading at Rs. 387.55, up by 0.65 points or 0.17% from its previous closing of Rs. 386.90 on the BSE.
The scrip opened at Rs. 383.00 and has touched a high and low of Rs. 396.00 and Rs. 383.00 respectively.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 400.35 on 05-Jun-2020 and a 52 week low of Rs. 211.30 on 20-Aug-2019.
Last one week high and low of the scrip stood at Rs. 396.00 and Rs. 378.10 respectively. The current market cap of the company is Rs. 46428.00 crore.
The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 22.30% and 17.03% respectively.
Biocon and Mylan N.V. have received an approval from the US Food and Drug Administration (USFDA) for the New Drug Application (NDA) for Semglee (insulin glargine injection), in vial and prefilled pen presentations, to control high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type 1 diabetes. Semglee has an identical amino acid sequence to Sanofi’s Lantus and is approved for the same indications.
Semglee, codeveloped by Mylan and Biocon Biologics, was approved as a drug product under the 505(b)(2) NDA pathway and is now deemed a biologic under section 351(a) in accordance with the Biologics Price Competition and Innovation Act in line with other insulin products.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovationdriven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
